Clinical trials: Rivaroxaban
Anticoagulation
A Nationwide Registry Study of Patients With Nonvalvular Atrial Fibrillation Initiating Oral Anticoagulation Therapies In The Early Period Following Apixaban Marketing In Denmark
The purpose of this study is to describe the characteristics of patients treated with different OATs and whether these characteristics differ between treatments.
- Trial name
- NCT02591732
- Where
- Denmark
- Volunteers
- 52,178 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
Satisfaction/Quality of Life With Rivaroxaban in SPAF (Stroke Prevention in Atrial Fibrillation) Indication
National, multicenter, prospective, observational, non-interventional study. The objective is to determine if the switch from Vitamin K antagonists (VKA) to Xarelto in subjects treated with VKA with issues for stroke prevention…
- Trial name
- SAFARI (NCT01805531)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- France
- Volunteers
- 411 people
- Sponsor
- Bayer
Atrial Fibrillation
Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation
This study is to evaluated the interruption schedule of NOAC in patients who undergo atrial fibrillation ablation. The investigators will compare the bleeding complications were classified as major and minor bleeding…
- Trial name
- NCT02504177
- Testing
- novel oral anticoagulant for 30 days, novel oral anticoagulant for 24 hour
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- Yonsei University
Atrial Fibrillation
Comparing the Safety and Efficacy of Apixaban and Rivaroxaban
The trial will compare two anticoagulants ("blood thinners") that are currently used in the VA and are considered standard care to prevent strokes in patients with atrial fibrillation.
- Trial name
- VALIANT-AF-T (NCT06953726)
- Testing
- Apixaban, Rivaroxaban
- Where
- 9 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- VA Office of Research and Development
Deep Vein Thrombosis
Venous Thromboembolism (VTE) Treatment Study in Japanese Deep Vein Thrombosis (DVT) Patients
The objective of this study is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of two different dosages of rivaroxaban in the treatment of deep vein thrombosis (DVT) and the prevention of the…
- Trial name
- NCT01516840
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Unfractionated heparin, Warfarin
- Where
- 29 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Bayer
Healthy
Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT
This study is a randomized, single-blind, placebo-controlled study to assess the efficacy and safety of ciraparantag administered to healthy volunteers anticoagulated with rivaroxaban measuring clotting times using Whole Blood…
- Trial name
- NCT03172910
- Testing
- Ciraparantag, Rivaroxaban
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.
Venous Thrombosis Due to Central Venous Access Device (Disorder), Prophylactic Anticoagulation
Prophylactic Anticoagulation for Catheter-related Thrombosis
The main objective of this study is to compare the efficacy and safety of aspirin, low molecule heparin and rivaroxaban for preventing catheter-related thrombosis in middle-to-high-risk ambulatory patients with cancer and…
- Conditions
- Venous Thrombosis Due to Central Venous Access Device (Disorder), Prophylactic Anticoagulation, Patients With Tumor
- Trial name
- NCT04256525
- Testing
- Rivaroxaban 10mg, Aspirin 100mg, low molecule heparin
- Where
- 28 sites in China
- Volunteers
- 1,640 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ischemic Stroke, Intracranial Hemorrhages
Novel Oral Anticoagulants in Stroke Patients
The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs.
- Trial name
- NOACISP (NCT02353585)
- Where
- Switzerland
- Volunteers
- 1,050 people
- Sponsor
- University Hospital, Basel, Switzerland
Pulmonary Embolism, Venous Thromboembolism
Rivaroxaban in Elderly Chinese Venous Thromboembolism Patients
There's no unified recommendation in clinical practice regarding adjusting dosages for different patient types, especially when adverse events occur.
- Conditions
- Pulmonary Embolism, Venous Thromboembolism, Anticoagulant-induced Bleeding
- Trial name
- NCT06194617
- Testing
- Direct oral anticoagulant
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Peking Union Medical College Hospital
Combined Anticoagulation and Antithrombotic Therapy, PAD - Peripheral Arterial Disease
Effectiveness of Combined Anticoagulation and Antithrombotic Therapy vs Antithrombotic Therapy Alone After Lower Extremity Revascularization for Peripheral Arterial Disease
EFFECTIVENESS OF COMBINED ANTICOAGULATION AND ANTITHROMBOTIC THERAPY VS ANTITHROMBOTIC THERAPY ALONE AFTER LOWER EXTREMITY REVASCULARIZATION FOR PERIPHERAL ARTERIAL DISEASE.
- Trial name
- NCT04994223
- Testing
- Rivaroxaban 10 MG Oral Tablet [Xarelto]
- Where
- Pakistan
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Armed Forces Post Graduate Medical Institute (AFPGMI), Rawalpindi
Acute Coronary Syndrome
Rivaroxaban in Combination With Aspirin Alone or With Aspirin and a Thienopyridine in Patients With Acute Coronary Syndromes (The ATLAS ACS TIMI 46 Trial)
The purpose of this study is to evaluate the safety of rivaroxaban in patients with recent acute coronary syndrome (ACS) and to assess the ability of rivaroxaban to reduce the occurrence of death, myocardial infarction (heart…
- Trial name
- NCT00402597
- Testing
- Rivaroxaban
- Volunteers
- 3,490 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Atrial Fibrillation
Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy
The study goal is to determine the clinical benefit of percutaneous catheter-based left atrial appendage (LAA) closure in patients with non-valvular atrial fibrillation (NVAF) at high risk of stroke (CHA2DS2-VASc Score ≥2) as…
- Trial name
- CLOSURE-AF (NCT03463317)
- Testing
- CE-mark approved LAA closure devices, Acetylsalicylic acid, Clopidogrel
- Where
- 42 sites in Germany
- Volunteers
- 912 people
- Sponsor
- Charite University, Berlin, Germany
May-Thurner Syndrome
Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study
The purpose of this study is to evaluate the efficacy and safety of rivaroxaban for the prevention of deep vein thrombosis in patients with left iliac vein compression treated with stent implantation.
- Trial name
- PLICTS (NCT04067505)
- Testing
- Rivaroxaban, Warfarin, Nadroparin
- Where
- 9 sites in China
- Volunteers
- 224 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ventricular Mural Thrombosis
An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)
To study the effect of rivaroxaban anticoagulant therapy for 12 weeks in patients with left ventricular mural thrombus by contrast echocardiography before and after treatment, so as to provide basis and foundation for further…
- Trial name
- R-DISSOLVE (NCT04970381)
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 75 people
- Sponsor
- China National Center for Cardiovascular Diseases
Heavy Menstrual Bleeding
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)
- Trial name
- NCT04477837
- Testing
- Apixaban 5 MG, Rivaroxaban 20 MG, Edoxaban 60 MG
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Non-Valvular Atrial Fibrillation (NVAF)
A Study of Participants With Non-Valvular Atrial Fibrillation (NVAF) Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
- Trial name
- NCT05027061
- Where
- Japan
- Volunteers
- 11,776 people
- Sponsor
- Bristol-Myers Squibb
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Stroke, Prevention
Rivaroxaban Plus ASA in Embolic Stroke of Undetermined Source(AREST-ESUS)
Approximately 17% of all patients with stroke are classified as having ESUS, which is associated with a considerable rate of stroke recurrence 4-5 % per year.
- Trial name
- AREST-ESUS (NCT04273516)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet
- Where
- Iran
- Volunteers
- 42 people
- Sponsor
- Mazandaran University of Medical Sciences
Coronary Artery Disease, Bleeding
Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures
Up to 20-30% of patients who are candidates for direct oral anticoagulation (DOAC) present with concomitant ischemic heart disease and often require coronary angiography with or without percutaneous coronary intervention (PCI).
- Conditions
- Coronary Artery Disease, Bleeding, Direct Acting Anticoagulant Adverse Reaction
- Trial name
- DOAC-NOSTOP (NCT05292846)
- Testing
- Direct-acting oral anticoagulation
- Where
- 4 sites in Italy, Spain
- Volunteers
- 200 people
- Sponsor
- Hospital Universitario La Fe
Stroke
Use of Direct Oral Anticoagulants in UK
Many people who suffer from irregular heartbeats (atrial fibrillation) which might cause stroke, need to take blood thinners to prevent it.
- Trial name
- NCT03119116
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Dabigatran, Apixaban
- Where
- United Kingdom
- Volunteers
- 31,336 people
- Sponsor
- Bayer